| Filed On | Filing |
|---|---|
| 14 Dec 2020 |
8-K/A: Financial Statements and Exhibits
On October 1, 2020, Cryoport, Inc. (the “Company” or “Cryoport”) completed its acquisition of CRYOPDP for a cash consideration of €49 million, subject to cash, net debt, working capital and other adjustments (the “CRYOPDP Acquisition”). ... |
| 08 May 2020 |
8-K/A: Results of Operations and Financial Condition
Revenue from commercial therapies increased 110% over the prior year |
| 03 Mar 2020 |
8-K/A: Submission of Matters to a Vote of Security Holders
At the Annual Meeting, the Company’s stockholders voted on, among other matters, an advisory proposal (the “Say-on-Frequency Proposal”) concerning the frequency of future advisory votes on executive compensation. As reported in the Initi... |
| 14 Jun 2019 |
8-K/A: Financial Statements and Exhibits
We have audited the accompanying balance sheets of CryoGene Partners (the “Company”), which comprise the balance sheets as of December 31, 2018 and 2017, and the related statements of income and partners’ capital, and cash flows for the ... |
| 16 Aug 2016 |
8-K/A: Results of Operations and Financial Condition
Company added 28 new biopharma clients during first three months of FY2017 and is supporting 23 of 28 leading CAR-T projects |
| 29 Feb 2008 | 8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more |
| 03 May 2007 |
8-K/A: Entry into a Material Definitive Agreement
On April 30, 2007, the Company mistakenly filed attachments to item 1.01 which were incomplete or incorrect. The corrected exhibits are attached hereto. |
Loading...